Skip to content
Catalyst

PapersPMID:32055589

Cognition enhancing effect of panax ginseng in Korean volunteers with mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial.

Translational and clinical pharmacology2019The record ↗

  1. Finding, moderate evidenceno difference foundMini-Mental State Examination total score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “In the repeated measures analysis, there were no statistically significant differences in K-MMSE and K-IADL between ginseng group and placebo group over time (P = 0.3197, P = 0.8842, ANOVA) (Table 4).”
    Study
    RCT
    Duration
    6 months
    Dose studied
    3.0 g per day Panax ginseng powder for 24 weeks (300 mg capsules)
    Population
    Korean adults aged 50 to 75 years with mild cognitive impairment (K-MMSE over 26 at enrolment), repeated-measures analysis across baseline, 16 and 24 weeks

Study record

Design
randomised controlled trial
Species
human
Population
Korean volunteers aged 50 to 75 years with mild cognitive impairment (MCI), K-MMSE over 26; Panax ginseng powder (4-year-old root)
Participants
90
Comparator
placebo
Duration
168 days
Endpoints measured
15